Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) Sellers Strengthened Their Shorts By 21.08%

June 27, 2018 - By Jeanette Garcia

Urogen Pharma LTD. – Ordinary Shares (NASDAQ:URGN) showed an increase of 21.08% in shorted shares. FINRA issued shorted shares of URGN’s total 236,100 shares. The up change of 21.08% from 195,000 shares was reported. With Average volume 120,000, URGN’s former position will take 2 days to restore. 2.77% is Urogen Pharma LTD. – Ordinary Shares float short.

The stock decreased 2.38% or $1.2 during the last trading session, reaching $49.27.UroGen Pharma Ltd. has volume of 76,670 shares. Since June 27, 2017 URGN has risen 228.14% and is uptrending. URGN outperformed by 215.57% the S&P500.

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing therapies for urological pathologies.The company has $762.40 million market cap. The Company’s lead product candidates, MitoGel and VesiGel are formulations of the chemotherapy drug Mitomycin C, a generic drug which is currently used off-label for urothelial cancer treatment only in a water formulation as an adjuvant, or supplemental post-surgery, therapy.Last it reported negative earnings. The firm is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.

For more UroGen Pharma Ltd. (NASDAQ:URGN) news posted briefly go to: Globenewswire.com, Nasdaq.com, Multichannel.com, Streetinsider.com or Nasdaq.com. The titles are as follows: “Investor Expectations to Drive Momentum within Mesoblast, Access National, Urogen Pharma, TechTarget, Sina, and …” posted on June 06, 2018, “UroGen Pharma’s Chairman, Arie Belldegrun, MD, FACS to Receive EY 2018 Master Entrepreneur Award” on June 13, 2018, “Qwilt Appoints Yoni Mizrahi as Chief Financial Officer” with a publish date: June 21, 2018, “UroGen Pharma (URGN) Names Stephen Mullennix Interim CFO, Replacing Gary Titus” and the last “UroGen Pharma to Present at the Jefferies 2018 Global Healthcare Conference” with publication date: May 29, 2018.

UroGen Pharma Ltd. (NASDAQ:URGN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.